Showing results (91-100 of 164) with videos related to

Sort By:
Pageof 17
Haematologica|July 21, 2018
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL groupLionel Adès, Xavier Thomas, Agnes Guerci Bresler, et al.
Annals of Intensive Care|September 18, 2016
Management of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French Society of Anesthesia and Intensive Care (SFAR), the French Society of Hematology (SFH), the French Society for Hospital Hygiene (SF2H), and the French Infectious Diseases Society (SPILF)David Schnell, Elie Azoulay, Dominique Benoit, et al.
Leukemia Research|November 22, 2019
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemiasAline Massé, Louise Roulin, Justine Pasanisi, et al.
Blood|June 22, 2011
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 studyXavier Thomas, Mohamed Elhamri, Emmanuel Raffoux, et al.
Cancers|January 8, 2020
Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex KaryotypeLaurène Fenwarth, Nicolas Duployez, Xavier Thomas, et al.
Biomedicines|November 27, 2021
Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)Hanane Djamai, Jeannig Berrou, Mélanie Dupont, et al.
Annals of Hematology|January 25, 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective studyLudovic Gabellier, Pierre Peterlin, Sylvain Thepot, et al.
Haematologica|October 17, 2024
Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropeniaFlorent Puisset, Emmanuel Raffoux, Lionel Ades, et al.
Blood|December 28, 2019
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemiaElise Fournier, Nicolas Duployez, Benoît Ducourneau, et al.
Haematologica|November 25, 2017
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic AnemiaEtienne Lengline, Bernard Drenou, Pierre Peterlin, et al.
Pageof 17